D. Boral Capital Reaffirms “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI)
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued on Monday,Benzinga reports. They currently have a $21.00 price objective on the stock. D. Boral Capital’s target price would indicate a potential upside of 252.94% from the stock’s current price. […]
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued on Monday,Benzinga reports. They currently have a $21.00 price objective on the stock. D. Boral Capital’s target price would indicate a potential upside of 252.94% from the stock’s current price. […]
